NCT06448910

Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

Lung-AK104 Study: Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage Lll Non-Small Cell Lung Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this single arm, phase II clinical trial is to evaluate the efficacy and safety of cadonilimab (AK104) as induction and consolidation therapy in locally advanced/unresectable non-small cell lung cancer (NSCLC) patients treated with concurrent chemoradiotherapy. Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide regimen chemotherapy), and finally consolidation therapy with cadonilimab (AK104) for 1 year.

Conditions

• NSCLC
• Locally Advanced Lung Carcinoma

Interventions

Type	Name	Description
DRUG	Cadonilimab (AK104)	Participants will receive 2 cycles of induction therapy with cadonilimab combined with carboplatin/cisplatin plus etoposide, followed by standard concurrent chemoradiotherapy (thoracic radiotherapy + carboplatin/cisplatin plus etoposide), and finally consolidation therapy with cadonilimab (AK104) for 1 year.

Timeline

• Start date: 2024-07-01
• Primary completion: 2025-10-01
• Completion: 2027-06-01
• First posted: 2024-06-07
• Last updated: 2025-09-24

Locations

1 site across 1 country: China